Ultragenyx Pharmaceutical Inc. (RARE) Earnings Call Transcripts
Ultragenyx Pharmaceutical Inc.'s Latest Earnings Call - June 9, 2026
In the Q2 2026 earnings call, Ultragenyx Pharmaceutical Inc. (RARE:US) emphasized its strategic positioning for profitability by 2027, driven by upcoming gene therapy launches and positive Phase II data for Angelman syndrome. The company reported a cash balance of $534 million and is anticipating significant revenue contributions from two potential Priority Review Vouchers (PRVs) expected to generate $200 million each. Management expressed confidence in upcoming Phase III data and the urgency surrounding their gene therapy products, which could transform the company's financial outlook.
Reported metrics
| Metric | Value |
|---|---|
| Cash Balance | $534 million (positive) |
| Projected Revenue from PRVs | $400 million (positive) |
| Revenue Growth Rate | 20% (positive) |
| PDUFA Dates | August and September 2026 (neutral) |
| Expected Improvement in Bayley-4 Score | 10 points (positive) |
| Patient Population for GSDIa | 1,500+ patients (positive) |
Guidance from management
Management maintained their guidance for profitability by 2027, emphasizing the importance of upcoming product approvals and the potential revenue from PRVs to support this goal.
What management said
Yes. We believe it hasn't I think the issue we are having based on the MRIs and everything else is pretty clear that there was local concentration of drug that was causing local chemical train. As long as the patients are put in tenor and the drug driven cranially to allow for rapid mixing. We seem to have eliminated that. And so we feel pretty comfortable, and we have patients now for 5 years on drug up to 5 years, ...
What analysts pressed on
Analysts expressed concerns regarding the potential for placebo effects in the Angelman study and the challenges in patient identification for Sanfilippo syndrome, highlighting the need for effective screening mechanisms to capture patients early.
Main topics on the call
- Path to Profitability — Management reiterated their goal of achieving profitability by 2027, stating, "if we get both approvals, we will have 2 PRBs we'd expect, which have been selling for very significant sum money." This indicates a strong f...
- Angelman Syndrome Phase III Study — The Phase III study for Angelman syndrome is on track, with management stating, "we feel comfortable with the strength of the study" and a projected 10-point improvement in cognitive function. This positions the company ...
- Gene Therapy Launch Dynamics — Ultragenyx is preparing for the launch of gene therapies for GSDIa and Sanfilippo syndrome, with management noting the urgency of treatment, particularly for Sanfilippo, stating, "there's a substantial urgency" for patie...
- Regulatory Strategy for Aurora Study — Management discussed the Aurora study's role in broadening the label for Angelman syndrome, indicating they are evaluating multiple endpoints to support regulatory filings. They believe the data will be sufficient for a ...
Read the full Ultragenyx Pharmaceutical Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 103 calls on record spanning January 9, 2020 to August 4, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 103 Ultragenyx Pharmaceutical Inc. earnings call transcripts on record, spanning January 9, 2020 to August 4, 2026. Based on this history, Ultragenyx Pharmaceutical Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RARE
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 103
- First call
- January 9, 2020
- Most recent
- August 4, 2026
- Reporting cadence
- quarterly